On the surface, Sun Pharmaceutical Industries Ltd’s US$3.2 billion purchase of Indian generics rival Ranbaxy Laboratories Ltd, which is in deep trouble with US regulators over safety lapses, may not look like a great deal.
Yet Sun Pharm’s shares rocketed on last week’s announcement that it was buying Ranbaxy from Japanese drugmaker Daiichi Sankyo Co, which struggled unsuccessfully to resolve the Indian company’s regulatory woes after its 2008 US$4.6 billion acquisition.
Investors gave the thumbs-up, banking on Sun’s history of nursing ailing companies back to health and the new clout it will gain in the fast-growing global generics market.
Photo: AFP
“It’s a risk, but well-calculated and backed by Sun’s track record of turning around troubled assets,” D.G. Shah, secretary-general of industry group Indian Pharmaceutical Alliance, told reporters.
Sun, with its decades of experience in formulating knock-off drugs that have brought it alliances with US giants such as Merck, “is like a white knight to bail out Ranbaxy from the FDA [US Food and Drug Administration] mess,” Shah said.
New Delhi-based Ranbaxy is unable to export drugs to its key US market from its four Indian manufacturing plants due to bans imposed by the FDA in relation to quality problems.
Mumbai-based Sun, founded three decades ago by tycoon Dilip Shanghvi, a billionaire with a shrewd reputation, says it is aware of the “magnitude” of Ranbaxy’s regulatory woes.
For Sun, pluses far outweigh minuses because the purchase will give it a broader range of drugs in its medicine cabinet, a robust pharmaceutical pipeline and a wider geographical reach, analysts say.
With the acquisition, Sun will be the world’s fifth-largest generic pharmaceutical company and nearly double its annual sales to US$4.2 billion. The merged company will have operations in 65 companies and 47 plants across five continents.
Crucially, it will also become the biggest Indian drugmaker by sales in the US and the largest domestically with a 9.2 percent market share, compared with Abbott Laboratories’ 6.5 percent, Mumbai’s Angel Broking said.
That difference represents a “huge gap in the highly fragmented Indian pharmaceutical market” where demand is accelerating, Angel Broking analyst Sarabjit Kour Nangra said.
Sun will also get much larger revenues from beyond India and the US, especially from emerging markets such as Russia and Brazil.
“In high-growth emerging markets which are 50 percent of Ranbaxy’s sales, it provides a strong platform which is highly complementary to Sun Pharma’s strengths,” Nangra said.
While Sun may have got a bargain, Daiichi Sankyo, which bought Ranbaxy to escape a saturating home market, is smarting from heavy losses from its Indian foray.
Daiichi paid US$4.6 billion for the Indian company and then took a US$3.8 billion writedown over Ranbaxy’s quality issues. Last year, Ranbaxy paid a US$500 million US fine for falsifying drug safety records.
Unable to clean up Ranbaxy amid what some analysts and observers termed “cultural issues” reflecting a clash of Indian and Japanese work cultures and geographic distance, Daiichi exited.
Daiichi president Joji Nakayama conceded that the company lost money in the deal, but told Japanese reporters: “We’ve learned a lot of things and got lots of ideas.”
Daiichi, which is set to obtain a 9 percent stake in the merged company, will also have “a partnership with a world-leading generic pharmaceutical firm,” Nakayama said.
Analysts said Daiichi’s small exposure would not make a big difference to its fortunes.
BUSINESS UPDATE: The iPhone assembler said operations outlook is expected to show quarter-on-quarter and year-on-year growth for the second quarter Hon Hai Precision Industry Co (鴻海精密) yesterday reported strong growth in sales last month, potentially raising expectations for iPhone sales while artificial intelligence (AI)-related business booms. The company, which assembles the majority of Apple Inc’s smartphones, reported a 19.03 percent rise in monthly sales to NT$510.9 billion (US$15.78 billion), from NT$429.22 billion in the same period last year. On a monthly basis, sales rose 14.16 percent, it said. The company in a statement said that last month’s revenue was a record-breaking April performance. Hon Hai, known also as Foxconn Technology Group (富士康科技集團), assembles most iPhones, but the company is diversifying its business to
Apple Inc has been developing a homegrown chip to run artificial intelligence (AI) tools in data centers, although it is unclear if the semiconductor would ever be deployed, the Wall Street Journal reported on Monday. The effort would build on Apple’s previous efforts to make in-house chips, which run in its iPhones, Macs and other devices, according to the Journal, which cited unidentified people familiar with the matter. The server project is code-named ACDC (Apple Chips in Data Center) within the company, aiming to utilize Apple’s expertise in chip design for the company’s server infrastructure, the newspaper said. While this initiative has been
GlobalWafers Co (環球晶圓), the world’s No. 3 silicon wafer supplier, yesterday said that revenue would rise moderately in the second half of this year, driven primarily by robust demand for advanced wafers used in high-bandwidth memory (HBM) chips, a key component of artificial intelligence (AI) technology. “The first quarter is the lowest point of this cycle. The second half will be better than the first for the whole semiconductor industry and for GlobalWafers,” chairwoman Doris Hsu (徐秀蘭) said during an online investors’ conference. “HBM would definitely be the key growth driver in the second half,” Hsu said. “That is our big hope
The consumer price index (CPI) last month eased to 1.95 percent, below the central bank’s 2 percent target, as food and entertainment cost increases decelerated, helped by stable egg prices, the Directorate-General of Budget, Accounting and Statistics (DGBAS) said yesterday. The slowdown bucked predictions by policymakers and academics that inflationary pressures would build up following double-digit electricity rate hikes on April 1. “The latest CPI data came after the cost of eating out and rent grew moderately amid mixed international raw material prices,” DGBAS official Tsao Chih-hung (曹志弘) told a news conference in Taipei. The central bank in March raised interest rates by